1. Skip to header
  2. Skip to main
  3. Skip to content
  4. Skip to sidebar
  5. Skip to footer
  • Home > Mesothelioma Clinical Trials

Mesothelioma Clinical Trials

PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery

Title: (Official)Phase II Study of PXD 101 (NSC 726630) as Second-Line Therapy for Treatment of Patients With Malignant Pleural Mesothelioma
Objective:Determine the objective response rate in patients with unresectable malignant pleural mesothelioma (MPM) treated with PXD101.
Location:Multi-center study, locations in:

  • California,
  • Pennsylvania.
Link:PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery

 

Flavopiridol in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies

Title: (Official)A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Novel Flavopiridol in Patients With Refractory Solid Tumors and Hematologic Malignancies
Objective:Determine the maximum tolerated dose of flavopiridol in patients with metastatic or unresectable refractory solid tumors or hematologic malignancies.
Location:Multinational study, with locations in Belgium, Italy, the Netherlands, England and Scotland.
Link:Flavopiridol in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies

 

Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma

Title: (Official)A Randomized Controlled Trial of Active Symptom Control With or Without Chemotherapy in the Treatment of Patients With Malignant Pleural Mesothelioma
Objective:Compare the overall survival of patients with malignant pleural mesothelioma treated with active symptom control (ASC) alone vs ASC and mitomycin, vinblastine, and cisplatin vs ASC and vinorelbine.
Location:England
Link: Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma

 

ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen

Title: (Official)ONCONASE Plus Doxorubicin Versus Doxorubicin For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen
Objective:
  • » Compare the efficacy of doxorubicin with or without Onconase in patients with malignant pleural or peritoneal mesothelioma.
  • » Compare the safety profile of these regimens in these patients.
  • » Compare the overall survival, progression-free survival, and quality of life of patients treated with these regimens.
Location:Multi-center study, locations in:

  • Indiana,
  • Maryland,
  • Michigan,
  • Minnesota,
  • Missouri,
  • Nebraska,
  • New Mexico,
  • German,
  • Italy,
  • Poland.
Link:ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen

 

EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer

Title:The Detection of Tumor Hypoxia and Vascularity in Patients Undergoing Intraperitoneal Photodynamic Therapy
Objective:
  • Determine the level of hypoxia through etanidazole derivative EF5 binding in patients with intraperitoneal or pleural malignancies treated with photodynamic therapy.
  • Determine the microvascular density in this patient population.
  • Determine the relationships between levels of hypoxia, measures of microvascular density, and photosensitizer levels in this patient population.
  • Correlate hypoxia and photosensitizer levels with clinical outcome in this patient population.
  • Determine the toxic effects of EF5 in this patient population.
Location:Pennsylvania
Link:EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer


Study of Patients With Non-Small Cell Lung Cancer, Esophageal Cancer, or Malignant Pleural Mesothelioma

Title: (Official)Prospective Evaluation of Epigenetic Alterations in Patients With Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas
Objective:
  • Evaluate patients referred to the Thoracic Oncology Section of the Surgery Branch, NCI in order to identify patients who are suitable candidates for clinical research protocols.
  • Obtain biopsies during staging studies of tumor and adjacent normal tissues as well as serum and urine samples from patients with primary aerodigestive tract malignancies to support preclinical research endeavors in the Thoracic Oncology Section.
  • Permit standard treatment for patients who are not eligible for investigational therapy on a current Thoracic Oncology protocol, but who present a novel and unique clinical training opportunity, or who manifest a clinical condition that requires immediate intervention to prevent compromise to the patient’s well-being.
Location:Maryland
Link:Study of Patients With Non-Small Cell Lung Cancer, Esophageal Cancer, or Malignant Pleural Mesothelioma

 

Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma

Title: (Official)Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Mesothelioma
Objective:
  • Provide treatment with antineoplastons A10 and AS2-1 to patients with stage IV mesothelioma.
  • Describe the response to, tolerance to, and side effects of this regimen in these patients.
Location:Texas
Link:Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma

 

Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have Diagnostic Procedures to Identify Malignant Mesothelioma

Title: (Official)A Randomized Study to Assess Whether Radiotherapy Prevents Skin Lumps at Sites Where Needles or Tubes Have Been Inserted in Patients With Malignant Mesothelioma
Objective:
  • Determine the efficacy of radiotherapy in the prevention of metastatic skin nodules or tumor seeding following invasive diagnostic procedures, such as chest drain insertion, pleural aspiration, pleural biopsy, and thoracoscopy, in patients with malignant mesothelioma.
  • Determine whether the nodules that develop after radiotherapy are symptomatic in these patients.
  • Compare the quality of life of patients treated with radiotherapy vs standard care alone.
Location:Scotland
Link: Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have Diagnostic Procedures to Identify Malignant Mesothelioma

 

Combination Chemotherapy in Treating Patients With Advanced Lung Cancer, Esophageal Cancer, Pleural Mesothelioma, or Lung Metastases

Title: (Official)Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion in Subjects With Pulmonary and Pleural Malignancies
Objective:
  • Determine the pharmacokinetics, toxicity, and maximum tolerated dose of decitabine and FR901228 (depsipeptide) in patients with unresectable pulmonary, esophageal, or pleural malignancies.
  • Determine serologic response to NY-ESO-1 in these patients before and after receiving this regimen.
  • Evaluate apoptosis in tumor biopsies of these patients before and after receiving this regimen.
Location:Maryland
Link:Combination Chemotherapy in Treating Patients With Advanced Lung Cancer, Esophageal Cancer, Pleural Mesothelioma, or Lung Metastases

 

FR901228 and Flavopiridol in Treating Patients With Advanced Lung, Esophageal, or Pleural Cancer

Title:Phase I Study Of Sequential Depsipeptide/Flavopiridol Infusion In Subjects With Malignancies Involving Lungs, Esophagus, Or Pleura
Objective:
  • Determine the maximum tolerated dose and dose-limiting toxic effects of FR901228 (depsipeptide) when administered with flavopiridol in patients with advanced primary lung or esophageal cancer, malignant pleural mesothelioma, or lung or pleural metastases.
  • Determine the pharmacokinetics of this regimen in these patients.
Location:Maryland
Link:FR901228 and Flavopiridol in Treating Patients With Advanced Lung, Esophageal, or Pleural Cancer


Pemetrexed Disodium and Either Gemcitabine or Carboplatin in Treating Patients With Advanced Malignant Pleural Mesothelioma

Title: (Official)Pemetrexed Plus Gemcitabine Or Carboplatin In Patients With Advanced Malignant Mesothelioma: A Randomized Phase II Trial
Objective:Compare the response rates in patients with advanced malignant mesothelioma of the pleura treated with pemetrexed disodium combined with either gemcitabine or carboplatin.
Location:Multi-center Study, locations in:

  • Delaware,
  • Florida,
  • Georgia,
  • Illinois,
  • Indiana,
  • Iowa,
  • Maryland,
  • Michigan,
  • Minnesota,
  • New Jersey,
  • New York ,
  • North Dakota,
  • Ohio,
  • Pennsylvania,
  • South Dakota,
  • Wisconsin.
Link:Pemetrexed Disodium and Either Gemcitabine or Carboplatin in Treating Patients With Advanced Malignant Pleural Mesothelioma

 

Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma

Title: (Official)A Phase II Study Of Sunitinib (Su11248; Nsc 736511; Ind 74019) in Patients With Advanced Malignant Pleural Mesothelioma
Objective:
  • Assess the efficacy of sunitinib malate, in terms of response rate (complete and partial), in patients with malignant pleural mesothelioma.
  • Assess the toxicity, safety, and tolerability of this drug in these patients.
  • Assess the duration of response or stable disease, stable disease rate, progression-free survival, and median and overall survival rates.
Location:***Not yet recruiting
Link:Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma

 

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma

Title: (Official)Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Thoracic and Myeloid Neoplasms
Objective:Determine the safety and immunogenicity of the Wilms tumor-1 analog peptide vaccine in patients with acute myeloid leukemia, myelodysplastic syndromes, non-small cell lung cancer, or mesothelioma.
Location:New York
Link: Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma

 

Early Diagnosis of Lung Cancer and Mesothelioma in Prior Asbestos Workers

Title: (Official)Early Diagnosis of Mesothelioma and Lung Cancer Following Asbestos Exposure Using Low-Dose Computed Tomography
Objective:Currently there is no accepted non-invasive tool for the early diagnosis of mesothelioma or lung cancer in asbestos-exposed subjects. In the last decade, low-dose computed tomography (LDCT) has been successfully developed and validated for the early diagnosis of lung cancer in high-risk smokers. Malignant mesothelioma might, in an early stage, resemble a benign pleural plaque, which is a common finding after asbestos exposure. We target to develop low-dose CT as a tool to serially image the pleural plaques, quantify their individual and overall volume, compute the growth rate with time, and, as such, identify the presence of mesothelioma early, before symptoms occur.
Location:Ontario, Canada
Link:Early Diagnosis of Lung Cancer and Mesothelioma in Prior Asbestos Workers

 

Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma

Title:A Phase II Trial of Cisplatin, Pemetrexed and Bevacizumab in Untreated Malignant Mesothelioma
Objective:To estimate the time to progression of cancer in patients with previously untreated mesothelioma receiving cisplatin, pemetrexed and bevacizumab.
Location:Texas
Link:Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma


A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer

Title: (Official)A Study of the Safety, Tolerability, and Pharmacokinetics of MORAb-009, a Chimeric Monoclonal Antibody, in Subjects With Advanced Mesothelin-Expressing Tumors
Objective:The purpose of this study is to establish the safest doses of an investigational drug called MORAb-009 in subjects with pancreatic cancer, mesothelioma, or certain types of ovarian or lung cancer. MORAb-009 is a monoclonal antibody that is directed to an antigen on the surface of these cancers.
Location:Multi-center Study, locations in:

  • Maryland and
  • Pennsylvania.
Link:A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer

 

Trial of Cisplatin, Imatinib Mesylate, and Pemetrexed in Malignant Mesothelioma Patients

Title: (Official)Phase I Trial of Cisplatin, Pemetrexed, and Imatinib Mesylate in Unresectable or Metastatic Malignant Mesothelioma
Objective:To determine the maximum tolerated dose of the combination of cisplatin, imatinib mesylate, and pemetrexed in metastatic malignant mesothelioma.
Location:Texas
Link:Trial of Cisplatin, Imatinib Mesylate, and Pemetrexed in Malignant Mesothelioma Patients

 

Suberoylanilide Hydroxamic Acid (SAHA) Versus Placebo in Advanced Malignant Pleural Mesothelioma

Title: (Official)A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Malignant Pleural Mesothelioma Previously Treated With Systemic Chemotherapy.
Objective:This is a study to determine the safety, tolerability, and anti-tumor effectiveness of an oral investigational drug, suberoylanilide hydroxamic acid, in the treatment of advanced malignant pleural mesothelioma.
Location:Multi-center study, locations in:

  • Alabama,
  • California,
  • Colorado,
  • Georgia,
  • Illinois,
  • Maryland,
  • Minnesota,
  • Missouri,
  • New York,
  • Ohio,
  • Oregon,
  • Pennsylvania,
  • Australia,
  • Quebec, Canada,
  • France,
  • Germany,
  • Italy,
  • Netherlands,
  • Spain,
  • Sweden, and
  • United Kingkom, Herforrshire.
Link: Suberoylanilide Hydroxamic Acid (SAHA) Versus Placebo in Advanced Malignant Pleural Mesothelioma

 

Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer

Title: (Official)A Trial of Active Intralymphatic Immunotherapy With Interferon-Treated Cells and Cyclophosphamide
Objective:Phase II trial to study the effectiveness of combining cyclophosphamide with tumor cell vaccine in treating patients who have metastatic cancer or cancer at high risk of recurrence.
Location:California
Link:Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer

 

Combination Chemotherapy With or Without Surgery and Radiation Therapy in Treating Patients With Mesothelioma That Can Be Removed By Surgery

Title:A Phase II Trial of Cisplatin, Pemetrexed and Bevacizumab in Untreated Malignant Mesothelioma
Objective:This randomized clinical trial is studying combination chemotherapy, surgery, and radiation therapy to see how well they work compared to combination chemotherapy alone in treating patients with mesothelioma that can be removed by surgery.
Location:England
Link:Combination Chemotherapy With or Without Surgery and Radiation Therapy in Treating Patients With Mesothelioma That Can Be Removed By Surgery


Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer

Title: (Official)Efficacy and Feasibility of a Psychosocial Intervention Within the CCOP Context: Evaluation of the Facing Forward Guide to Facilitate Life After Active Cancer Treatment
Objective:This randomized phase III trial is studying how well printed education materials work in assisting patients who are finishing treatment for stage I, stage II, or stage IIIA breast cancer, colorectal cancer, prostate cancer, or chest cancer to make the transition from cancer patient to cancer survivor easier.
Location:Pennsylvania
Link:Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer

 

Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors

Title: (Official)Phase I Clinical Trial of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With Pemetrexed and Cisplatin in Patients With Advanced Cancer
Objective:The purpose of this investigational study is to determine the safety and tolerability of oral suberoylanilide hydroxamic acid when administered in combination with standard doses of pemetrexed and cisplatin for the treatment of advanced solid tumors.
Location:Multi-center study, locations in:

  • Alabama,
  • Nevada, and
  • Texas.
Link:Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors

 

Pemetrexed Plus Cisplatin Neoadjuvant Therapy Followed By Surgery and Radiation in Mesothelioma

Title: (Official)Phase II Trial of Neoadjuvant ALIMTA Plus Cisplatin Followed by Surgery and Radiation in the Treatment of Pleural Mesothelioma
Objective:To determine the event-free survival of patients with clinical stage I, II, or III (T1-3 N0-2) pleural mesothelioma treated with pre-operative chemotherapy (pemetrexed plus cisplatin), surgery (EPP) and hemithoracic radiation.
Location:Italy
Link: Pemetrexed Plus Cisplatin Neoadjuvant Therapy Followed By Surgery and Radiation in Mesothelioma

 

Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen

Title: (Official)A Phase 2 Study of ALIMTA in Solid Tumor Patients With Stable Third-Space Fluid
Objective:This study will test the effects of pemetrexed on mesothelioma and lung cancer patients with fluid around their lungs or abdomen.
Location:Multi-center study, locations in:

  • Denmark,
  • Germany and
  • Spain.
Link:Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen

 

Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma

Title:Phase II Study of the Combination of Bevacizumab Plus Pemetrexed and Carboplatin as First-Line Therapy in Patients With Malignant Pleural Mesothelioma
Objective:The primary objective is to assess antitumor activity of the combination of bevacizumab, pemetrexed and carboplatin, in terms of time to progression.
Location:** This study is not yet recruiting patients.(Italy)
Link:Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma


Surgery Plus IPHC to Treat Peritoneal Carcinomatosis

Title: (Official)Cytoreductive Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy for the Treatment of Peritoneal Carcinomatosis From Gastrointestinal Cancer: an Open Label, Randomized, Prospective, Phase 2 Clinical Trial
Objective:
  • » Determine response and survival of patients with peritoneal carcinomatosis treated with cytoreductive surgery plus intraoperative peritoneal hyperthermic chemotherapy with cisplatin and mitomycin.
  • » Assess the quality of life of patients treated with this regimen.
Location:China, Hubei
Link:Surgery Plus IPHC to Treat Peritoneal Carcinomatosis

 

Gene Therapy for Pleural Malignancies

Title: (Official)A Phase I Clinical Trial of Repeated Dose Intrapleural Adenoviral-Mediated Interferon-Beta (BG00001, Ad.hIFN-β for Pleural Malignancies
Objective:This Phase I study will evaluate the safety of two doses of BG00001.
Location:Pennsylvania
Link:Gene Therapy for Pleural Malignancies

 

Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining

Title: (Official)Prospective Evaluation of Epigenetic Alterations in Patients With Thoracic Malignancies
Objective:This study will evaluate individuals with cancer of the lung, lung lining or esophagus for participation in clinical trials conducted by the NCI. It will also use tissue obtained from disease staging procedures to examine cellular changes in blood and tissue in these cancers. Information from these studies may be useful in developing new treatments for these diseases.
Location:Maryland
Link: Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining

 

Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma

Title: (Official)Phase II Study of Carboplatin and Vinorelbine i.v. (Day 1) and Orally (Day 8) for Malignant Pleural Mesothelioma.
Objective:The purpose is to evaluate the activity and feasibility of a two drug regimen which is partly orally and partly intraveneous in advanced pleural mesothelioma.
Location:Denmark
Link:Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma

 

Dendritic Cell-Based Immunotherapy in Mesothelioma

Title:Vaccination With Autologous Dendritic Cells Pulsed With Tumor Lysate for Treatment of Patients With Malignant Pleural Mesothelioma
Objective:Exploiting the immunostimulatory capacities of dendritic cells holds great promise for cancer immunotherapy. A mouse model for malignant mesothelioma allowed us to prove that autologous dendritic cells presenting tumor antigens were very effective by (partly) inhibiting tumor growth. This study will test the feasibility and safety of a clinical trial using autologous DC as a therapeutic adjuvant for the treatment of malignant pleural mesothelioma.
Location:Netherlands, Zuid-Holland
Link:Dendritic Cell-Based Immunotherapy in Mesothelioma


Phase I Study of PXD101 in Patients With Advanced Solid Tumors

Title: (Official)Open Label, Dose Escalation Trial of Oral PXD101 in Patients With Advanced Solid Tumors
Objective:Phase I dose escalation study of PXD101 administered orally. The objectives are to determine safety, tolerability and pharmacokinetics, and establish a Maximum Tolerated Dose (MTD) for once daily dosing and twice daily dosing in patients with advanced solid tumors.
Location:Multi-center study, locations in:

  • Connecticut,
  • New York,
  • Texas,
  • Denmark and
  • United Kingdom, Surrey.
Link:Phase I Study of PXD101 in Patients With Advanced Solid Tumors

 

Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors

Title: (Official)A Phase I Safety, Pharmacodynamic, Anti-Tumor Activity, and Pharmacokinetic Study of PXD101 Alone and in Combination With 5-Fluorouracil in Patients With Advanced Solid Tumors
Objective:This is a safety study in patients with advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor activity, and how the study drug behaves within the body. A total of up to 40 patients is planned for enrollment.
Location:Multi-center study, locations in:

  • Arizonaa,
  • Nebraska and
  • New Hampshire.
Link:Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors

 

Ph Ib Rapamycin With Grapefruit Juice for Advanced Malignancies

Title: (Official)A Phase Ib Study Administering Rapamycin (Sirolimus) With Grapefruit Juice in Patients With Advanced Malignancies
Objective:The purpose of this study is to determine the highest safe dose of rapamycin when given with a fixed amount of grapefruit juice.
Location:Illinois
Link: Ph Ib Rapamycin With Grapefruit Juice for Advanced Malignancies

 

An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation

Title: (Official)An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation
Objective:Doctors will take some tissue from the tissue removed during surgery in order to study how the blood vessels of the tumor respond to radiation therapy. The tissue obtained will be used to determine how these tumor blood vessels respond to radiation therapy delivered to the tumor, after it has been removed. This radiation is delivered in the research lab. This research is being conducted in order to develop new methods to treat tumors by radiation therapy. No additional surgery will be performed to obtain these samples, and only materials that remain after all diagnostic testing has been completed will be used.
Location:New York
Link:An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation

 

Open – Label Study of Alimta (pemetrexed) Combination with Cisplatin for Chemonaive Patients with Malignant Pleural Mesothelioma.

Title:Open – Label Study of Alimta (pemetrexed) Combination with Cisplatin for Chemonaive Patients with Malignant Pleural Mesothelioma
Objective:The purpose of this protocol is to extend the clinical experience with ALIMTA plus Cisplatin in patients with malignant pleural mesothelioma.
Location:New York
Link:Open – Label Study of Alimta (pemetrexed) Combination with Cisplatin for Chemonaive Patients with Malignant Pleural Mesothelioma


Phase II Trial of Combined Resection, Intraperitoneal Chemotherapy, and Whole Abdominal Radiation for Treatment of Peritoneal Mesothelioma

Title: (Official)Trial of Combined Resection, Intraperitoneal Chemotherapy, and Whole Abdominal Radiation for Treatment of Peritoneal Mesothelioma
Objective:Patients will be adults who have histologically confirmed malignant abdominal mesothelioma and will have received 0-2 prior chemotherapeutic regimens. Referral from the consultation service may take place only with the agreement of the responsible attending physician.All patients will undergo exploratory laparotomy. An attempt will be made to remove all nodules of greater than 1 cm in diameter. Approximately three to four weeks following surgery, intraperitoneal chemotherapy will be initiated weekly for twelve weeks. Following the intraperitoneal chemotherapy, patient will receive intraperitoneal immunotherapy weekly for four weeks.
Location:New York
Link:Trial of Combined Resection, Intraperitoneal Chemotherapy, and Whole Abdominal Radiation for Treatment of Peritoneal Mesothelioma

 

Oxaliplatin (ELOXATIN®) Plus Gemcitabine as First or Second-line Chemotherapy for Patients with Malignant Pleural or Peritoneal Mesothelioma. A Phase II Clinical Trial

Title: (Official)Oxaliplatin (ELOXATIN®) Plus Gemcitabine as First or Second-line Chemotherapy for Patients with Malignant Pleural or Peritoneal Mesothelioma. A Phase II Clinical Trial
Objective:The primary goal of this study is to determine the objective tumor response rate for Oxaliplatin plus gemcitabine in patients with malignant pleural mesothelioma and/or malignant peritoneal mesothelioma who have no more than one prior chemotherapy regimen and to record median survival for treated patients.
Location:New York
Link:Oxaliplatin (ELOXATIN®) Plus Gemcitabine as First or Second-line Chemotherapy for Patients with Malignant Pleural or Peritoneal Mesothelioma. A Phase II Clinical Trial

PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery

Title: (Official)Phase II Study of PXD 101 (NSC 726630) as Second-Line Therapy for Treatment of Patients With Malignant Pleural Mesothelioma
Objective:Determine the objective response rate in patients with unresectable malignant pleural mesothelioma (MPM) treated with PXD101.
Location:Multi-center study, locations in:

  • California,
  • Pennsylvania.
Link:PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery

Flavopiridol in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies

Title: (Official)A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Novel Flavopiridol in Patients With Refractory Solid Tumors and Hematologic Malignancies
Objective:Determine the maximum tolerated dose of flavopiridol in patients with metastatic or unresectable refractory solid tumors or hematologic malignancies.
Location:Multinational study, with locations in Belgium, Italy, the Netherlands, England and Scotland.
Link:Flavopiridol in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies

Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma

Title: (Official)A Randomized Controlled Trial of Active Symptom Control With or Without Chemotherapy in the Treatment of Patients With Malignant Pleural Mesothelioma
Objective:Compare the overall survival of patients with malignant pleural mesothelioma treated with active symptom control (ASC) alone vs ASC and mitomycin, vinblastine, and cisplatin vs ASC and vinorelbine.
Location:England
Link:Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma

ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen

Title: (Official)ONCONASE Plus Doxorubicin Versus Doxorubicin For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen
Objective:
  • Compare the efficacy of doxorubicin with or without Onconase in patients with malignant pleural or peritoneal mesothelioma.
  • Compare the safety profile of these regimens in these patients.
  • Compare the overall survival, progression-free survival, and quality of life of patients treated with these regimens.
Location:Multi-center study, locations in:

  • Indiana,
  • Maryland,
  • Michigan,
  • Minnesota,
  • Missouri,
  • Nebraska,
  • New Mexico,
  • German,
  • Italy,
  • Poland.
Link:ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen

EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer

Title:The Detection of Tumor Hypoxia and Vascularity in Patients Undergoing Intraperitoneal Photodynamic Therapy
Objective:
  • Determine the level of hypoxia through etanidazole derivative EF5 binding in patients with intraperitoneal or pleural malignancies treated with photodynamic therapy.
  • Determine the microvascular density in this patient population.
  • Determine the relationships between levels of hypoxia, measures of microvascular density, and photosensitizer levels in this patient population.
  • Correlate hypoxia and photosensitizer levels with clinical outcome in this patient population.
  • Determine the toxic effects of EF5 in this patient population.
Location:Pennsylvania
Link: 

 

 

EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer